Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Monitoreo Inmunológico y Retiro de CNI en Receptores de Trasplante Renal de Bajo Riesgo

22 de septiembre de 2026 actualizado por: National Institute of Allergy and Infectious Diseases (NIAID)

Monitoreo Inmunológico y Retiro del Inhibidor de Calcineurina (CNI) en Receptores de Trasplante Renal de Bajo Riesgo

The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.

Descripción general del estudio

Descripción detallada

Kidney transplantation is a treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects. The purpose of this study is to evaluate the safety of slowly removing tacrolimus, a CNI.

Tipo de estudio

Intervencionista

Inscripción (Actual)

52

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Manitoba
      • Winnipeg, Manitoba, Canadá, R3A IR9
        • Health Sciences Centre
    • Ontario
      • Toronto, Ontario, Canadá, M5G 2M1
        • Toronto General Hospital
    • California
      • Los Angeles, California, Estados Unidos, 90055
        • University of California Los Angeles
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520-8029
        • Yale University School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham & Women's Hospital
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan Hospital
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University
    • New York
      • New York, New York, Estados Unidos, 10029
        • Mount Sinai School of Medicine
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Estados Unidos, 44106-5048
        • University Hospitals of Cleveland
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • The Methodist Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

INCLUSION CRITERIA -

Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:

  • Subject must be able to understand and provide written informed consent;
  • Primary living-donor (related or unrelated) kidney transplant recipients;
  • Peak flow-based PRAs for class I and class II <30%(performed by local center);
  • Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II <30% (performed by local center);
  • No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;
  • Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);
  • Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;
  • Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.

Inclusion Criteria for Randomization:

Participants who meet all of the following criteria are eligible for randomization:

  • No history of acute rejection episodes;
  • The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);
  • No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).

EXCLUSION CRITERIA -

Initial Enrollment/Screening:

Participants who meet any of these criteria are not eligible for enrollment as study subjects:

  • Recipient of multiple organ transplants;
  • Prior history of organ transplantation;
  • Deceased-donor source;
  • Any condition that would preclude protocol biopsies;
  • HLA identical recipients;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness to comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.

Exclusion Criteria for Randomization:

Participants who meet any of these criteria are not eligible for randomization:

  • Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;
  • Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;
  • Any condition that would preclude protocol biopsies;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness of a subject to give written informed consent or comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tacrolimus (CNI) Withdrawal

Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.

Otros nombres:
  • Thymoglobulin®
  • micofenolato de mofetilo
  • CellCept®
  • Inducción de ATG, tacrolimus (CNI), MMF y prednisona, seguida de retirada de CNI
  • globulina antitimocito de conejo (RATG)
  • inhibidor de la calcineurina (CNI)

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Otros nombres:
  • Thymoglobulin®
  • micofenolato de mofetilo
  • CellCept®
  • globulina antitimocito de conejo (RATG)
  • inhibidor de la calcineurina (CNI)
  • Inducción ATG, Tacrolimus (CNI), MMF y Prednisona
Comparador activo: Standard Immunosuppressive Therapy

Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Otros nombres:
  • Thymoglobulin®
  • micofenolato de mofetilo
  • CellCept®
  • globulina antitimocito de conejo (RATG)
  • inhibidor de la calcineurina (CNI)
  • Inducción ATG, Tacrolimus (CNI), MMF y Prednisona

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants With Incremental IF/A Scores >2 at 24 Months Post-Randomization
Periodo de tiempo: IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

The investigators were not able to assess this outcome, the effect of the intervention on interstitial fibrosis/tubular atrophy (IF/TA; on a 2-year graft biopsy) due to the study's premature termination by the Data Safety Monitoring Board (DSMB) because of absence of equipoise on the basis of predetermined stopping rules.

IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Estimated GFR Using the Chronic Kidney Disease Epidemiology (CKD-EPI) Equation
Periodo de tiempo: 6 months post-transplantation, 24 months post-transplantation

Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function. In this measure, the effects of tacrolimus withdrawal on long-term kidney function was assessed by comparing absolute 24 month eGFR (18 months post-randomization) and change in eGFR from 6 to 24 months (randomization to 18 months randomization). Lower numbers indicate poorer kidney function

6 months post-transplantation, 24 months post-transplantation
Incidence of Acute Rejection
Periodo de tiempo: 6 to 18 months post-randomization

Acute renal allograft rejection is defined as histological reading of borderline or greater determined by the local pathology laboratory. Participants suspected of having a rejection episode on the basis of clinical signs, symptoms, or on the basis of laboratory tests, had a renal ultrasound and underwent a renal transplant biopsy. Any detection of acute cellular rejection or acute humoral rejection resulted in participants in the 'Randomized to Tacrolimus Withdrawal' group to be restarted on tacrolimus and followed per the reduced follow-up schedule of events.

6 to 18 months post-randomization
Allograft Survival Rate
Periodo de tiempo: 6 to 18 months post-randomization

Allograft survival is defined as participants who did not need to be re-transplanted or placed on dialysis due to the failure of their allograft transplantation during the course of this study.

6 to 18 months post-randomization
Participant Survival Rate
Periodo de tiempo: 6 to 18 months post-transplantation

Number of participants who did not die within the course of this study.

6 to 18 months post-transplantation
Percentage of Participants With New Donor Specific Antibodies (DSAs)
Periodo de tiempo: 6 to 18 months post-randomization

Donor specific antibodies are antibodies that are directed against antigens expressed on donor organs. These antibodies can result in an immune attack on the transplanted organ, increasing risk of graft loss and/or rejection.

6 to 18 months post-randomization
Percentage of Participants With Donor-Specific Memory Using Elispot
Periodo de tiempo: 6 to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-randomization
Percentage of Participants in the Experimental Arm Off Tacrolimus
Periodo de tiempo: 18 months post-randomization

Participants in the 'Randomized to Tacrolimus Withdrawal' group were considered fully withdrawn once they no longer received any doses of tacrolimus. Participants met this endpoint if they did not resume taking tacrolimus as of 18 months post randomization with stable allograft function and without rejection of donor-specific antibodies.

18 months post-randomization
Incremental Change in IF/TA Scores
Periodo de tiempo: 6 to 18 months post-transplant

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-transplant
Measurement of Urinary Parameters Before and After Randomization
Periodo de tiempo: 6 months post-transplantation to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 months post-transplantation to 18 months post-randomization

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Donald Hricik, MD, University Hospitals Cleveland Medical Center
  • Investigador principal: Peter S. Heeger, MD, Icahn School of Medicine at Mount Sinai

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de noviembre de 2010

Finalización primaria (Actual)

1 de mayo de 2015

Finalización del estudio (Actual)

1 de mayo de 2015

Fechas de registro del estudio

Enviado por primera vez

20 de enero de 2012

Primero enviado que cumplió con los criterios de control de calidad

20 de enero de 2012

Publicado por primera vez (Estimado)

25 de enero de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir